analyzed FDX1 expression data from The Cancer Genome Atlas (TCGA) for patients with HCC, and found that overall survival (OS), progression-free interval (PFI), disease-specific survival (DSS), and disease-free interval (DFI) were significantly better in patients with high FDX1 expression than in those with low FDX1 expression (126). Here, FDX1 is linked to hepatocellular carcinoma.